Tuberculosis in liver transplant recipients: A systematic review and meta-analysis of individual patient data
- 1 August 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 15 (8) , 894-906
Abstract
Mycobacterium tuberculosis (MTB) causes substantial morbidity and mortality in liver transplant recipients. We examined the efficacy of isoniazid latent Mycobacterium tuberculosis infection (LTBI) treatment in liver transplant recipients and reviewed systematically all cases of active MTB infection in this population. We found 7 studies that evaluated LTBI treatment and 139 cases of active MTB infection in liver transplant recipients. Isoniazid LTBI treatment was associated with reduced MTB reactivation in transplant patients with latent MTB risk factors (0.0% versus 8.2%, P = 0.02), and isoniazid-related hepatotoxicity occurred in 6% of treated patients, with no reported deaths. The prevalence of active MTB infection in transplant recipients was 1.3%. Nearly half of all recipients with active MTB infection had an identifiable pretransplant MTB risk factor. Among recipients who developed active MTB infection, extrapulmonary involvement was common (67%), including multiorgan disease (27%). The short-term mortality rate was 31%. Surviving patients were more likely to have received 3 or more drugs for MTB induction therapy (P = 0.003) and to have been diagnosed within 1 month of symptom onset (P = 0.01) and were less likely to have multiorgan disease (P = 0.01) or to have experienced episodes of acute transplant rejection (P = 0.02). Compared with the general population, liver transplant recipients have an 18-fold increase in the prevalence of active MTB infection and a 4-fold increase in the case-fatality rate. For high-risk transplant candidates, isoniazid appears safe and is probably effective at reducing MTB reactivation. All liver transplant candidates should receive a tuberculin skin test, and isoniazid LTBI treatment should be given to patients with a positive skin test result or MTB pretransplant risk factors, barring a specific contraindication. Liver Transpl 15:894–906, 2009. © 2009 AASLD.Keywords
Funding Information
- Department of Veterans Affairs
This publication has 95 references indexed in Scilit:
- Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS databaseLiver Transplantation, 2004
- Causes of death after liver transplantation in 4000 consecutive patients: 2 to 19 year follow-upTransplantation Proceedings, 2001
- THE CURRENT MANAGEMENT OF INFECTIOUS DISEASES IN THE LIVER TRANSPLANT RECIPIENTClinics in Liver Disease, 2000
- Infección después del trasplante hepático ortotópico: análisis de los 120 primeros casos consecutivosRevista Clínica Española, 2000
- Tuberculosis in liver transplant patientsTransplantation Proceedings, 1999
- Global Burden of TuberculosisJAMA, 1999
- Mycobacterium tuberculosisInfection in Solid‐Organ Transplant Recipients: Impact and Implications for ManagementClinical Infectious Diseases, 1998
- The Impact of Comorbidity on Mortality Following In-hospital Diagnosis of TuberculosisChest, 1998
- Prophylaxis with Isoniazid in Inactive TuberculosisChest, 1978
- Criteria for Prophylaxis in Inactive TuberculosisArchives of Environmental Health: An International Journal, 1965